Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $63.0 million.

  • Foghorn Therapeutics' Shares Outstanding (Diluted Average) rose 0.68% to $63.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.0 million, marking a year-over-year increase of 0.68%. This contributed to the annual value of $54.9 million for FY2024, which is 30.79% up from last year.
  • Foghorn Therapeutics' Shares Outstanding (Diluted Average) amounted to $63.0 million in Q3 2025, which was up 0.08% from $63.0 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Shares Outstanding (Diluted Average) peaked at $63.0 million during Q3 2025, and registered a low of $36.8 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $51.6 million, with a median of $51.6 million in 2024.
  • Data for Foghorn Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY spiked of 579.99% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' Shares Outstanding (Diluted Average) stood at $37.2 million in 2021, then grew by 11.89% to $41.6 million in 2022, then increased by 0.92% to $42.0 million in 2023, then soared by 30.79% to $54.9 million in 2024, then climbed by 0.68% to $63.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $63.0 million in Q3 2025, compared to $63.0 million in Q2 2025 and $62.8 million in Q1 2025.